ULTRA-RARE CANCERRare CarcinomaWHO 5th Edition Classification

Midline NUT Carcinoma

Ultra-Rare Malignancy (< 1 case per 1,000,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

A very aggressive squamous carcinoma defined by rearrangement of the NUTM1 gene, most often fused to BRD4. It arises along the midline - sinonasal tract, mediastinum, lung - and is frequently mistaken for poorly differentiated squamous cell carcinoma unless NUT immunohistochemistry is specifically requested.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Undifferentiated midline carcinoma in a young patient - request NUT IHC
  • Superior vena cava obstruction
Who It Affects

Any age; median in the 20s-30s, but reported from infancy to old age

Annual Incidence

Genuinely unknown - substantially under-diagnosed without NUT IHC

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Rapidly enlarging neck, sinus or chest mass
Nasal obstruction or epistaxis
Cough, chest pain, breathlessness
Superior vena cava obstruction (facial swelling, distended neck veins)
Bone pain from early metastasis

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

NUTM1 rearrangementBRD4-NUTM1 fusionBRD3-NUTM1 fusionNSD3-NUTM1 fusion

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Surgery where the tumour is resectable

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Intensive platinum-based chemotherapy

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Radiotherapy for local control

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

BET inhibitor or HDAC inhibitor clinical trials

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Early palliative care given the pace of the disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Poor. Median overall survival is around 6-7 months, though a minority of patients with resectable non-thoracic disease treated aggressively do considerably better.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

BET bromodomain inhibitors are the rational targeted approach and remain in trials; combinations with HDAC inhibition and CDK9 blockade are being explored.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Midline NUT Carcinoma

Browse All Oncologists

Dr. Jia Luo

Medical Oncologist, Thoracic Oncology

15+ yrs exp

Dana-Farber Cancer Institute

Boston, USA

Thoracic OncologyNUT CarcinomaRare Carcinomas
Vetted DirectoryConsult Specialist

Dr. Toh Chee Keong

Senior Consultant Medical Oncologist

20+ yrs exp

NCCS/OncoCare

Singapore, Singapore

Thoracic OncologyHead & Neck CancersNUT Carcinoma
Vetted DirectoryConsult Specialist

Prof. Lisa Licitra

Head of Head & Neck Oncology

30+ yrs exp

Istituto Nazionale Tumori

Milan, Italy

Head & Neck OncologyRare Head-Neck CancersNUT Carcinoma
Vetted DirectoryConsult Specialist

Dr. Anil D'Cruz

Surgical Oncologist, Ex-Director

33+ yrs exp

Tata Memorial Hospital

Mumbai, India

Head-Neck CancerSurgical OncologyNUT Carcinoma
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

ultra-rare

Malignant Rhabdoid Tumor

ultra-rare

Hepatosplenic T-cell Lymphoma (HSTCL)

ultra-rare

T-cell Prolymphocytic Leukemia (T-PLL)

ultra-rare

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Independent Tumor Board Review

Facing a Diagnosis of Midline NUT Carcinoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult